

November 7, 2002

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835

RE:

Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a manufacturer and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ostivone®	Ipriflavone	Ostivone® features ipriflavone, which has been shown in more than 60 studies to support bone mineral density.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

BA: KTACIA

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 11/7/02

Michael P. Devereux

Chief Financial Officer

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

Green Bay, WI 54311-8328

,,

825 Challenger Drive

Ph: 920-469-1313 Fax: 888-570-6460

www.enzy.com

Ostivone 5e

978 0162

LET //223

82465